Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Masimo's MightySat Medical is the first FDA-cleared pulse oximeter available to consumers without a prescription, which could disrupt the market for the notoriously inaccurate at-home devices.
MediView’s technologies utilize AR to provide clinicians with 3D “X-ray vision” guidance during minimally invasive procedures and surgeries, while also offering remote collaboration.
Many organizations are thinking about population health and consider it “critically important” to the future of healthcare, but few are in any payer agreements, according to findings from Numerof & Associates.
An article published earlier this week by Crain’s New York Business examined the two extremes of New York hospitals and a possible way to close that gap.
Medical technology company Stryker plans to acquire Cary, Ill.–based Sage Products, which manufactures a host of products meant to prevent so-called “never events” in ICUs and hospitals, including hospital-acquired infections.
Partners HealthCare is launching a second round of Innovation Discovery Grants (IDG) to support the most promising early-stage ideas that can someday improve patient care.
In an effort to better educate doctors and their patients about the Zika virus, the American Medical Association (AMA) announced today the creation of the Zika Virus Resource Center.
The Center for Data Driven Discovery in Biomedicine at The Children's Hospital of Philadelphia (CHOP) aims to advance precision medicine and match the most appropriate treatment to individual patients.
All adults age 18 and older in the general population—including pregnant and postpartum women—should be screened for depression, according to newly updated guidelines from the United States Preventative Services Task Force (USPSTF).
The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.
The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks.
Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.